Codagenix, Inc
Codagenix is a pioneering biotechnology company that combines synthetic biology, live-attenuated virus design, and cutting-edge technology to develop vaccines and therapeutics for infectious diseases, cancer, and animal health. Their platform enables rapid, scalable, and safe vaccine development, aiming to address global health challenges efficiently.
Industries
Nr. of Employees
small (1-50)
Patents
Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
US-12178869-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-12054519-B2
View DetailsLive attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
US-11793870-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-11390651-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-10808012-B2
View Details
Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
US-12178869-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-12054519-B2
View DetailsLive attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
US-11793870-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-11390651-B2
View DetailsVaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
US-10808012-B2
View DetailsProducts
Intranasal live-attenuated SARS-CoV-2 vaccine candidate
An intranasal live-attenuated vaccine candidate designed by genome recoding to induce broad antibody and T-cell responses against SARS-CoV-2 and formulated for refrigerated storage.
Codon-deoptimized RSV live-attenuated vaccine candidate
A codon-deoptimized live-attenuated respiratory syncytial virus vaccine candidate developed for elderly and pediatric indications, with Phase I clinical data reporting safety and cellular immune responses.
Live-attenuated universal influenza vaccine candidate (H1N1-derived)
A live-attenuated influenza vaccine candidate designed to present conserved antigens for multi-season protection and demonstrated multi-season efficacy in animal models at ultralow doses.
Tetravalent dengue live-attenuated vaccine candidate
A balanced quadrivalent dengue vaccine constructed by recoding contemporary dengue strains to generate safe and immunogenic vaccine components in non-human primates.
Zika live-attenuated vaccine candidate
A codon-deoptimized Zika vaccine candidate demonstrating safety and immunogenicity in non-human primate studies.
Foot-and-mouth disease (FMDV) multivalent vaccine candidate for livestock
Synthetic multivalent live-attenuated vaccine constructs for FMDV designed for livestock, developed in cooperation with agricultural research partners and aimed at scalable cell-culture production.
Intranasal live-attenuated SARS-CoV-2 vaccine candidate
An intranasal live-attenuated vaccine candidate designed by genome recoding to induce broad antibody and T-cell responses against SARS-CoV-2 and formulated for refrigerated storage.
Codon-deoptimized RSV live-attenuated vaccine candidate
A codon-deoptimized live-attenuated respiratory syncytial virus vaccine candidate developed for elderly and pediatric indications, with Phase I clinical data reporting safety and cellular immune responses.
Live-attenuated universal influenza vaccine candidate (H1N1-derived)
A live-attenuated influenza vaccine candidate designed to present conserved antigens for multi-season protection and demonstrated multi-season efficacy in animal models at ultralow doses.
Tetravalent dengue live-attenuated vaccine candidate
A balanced quadrivalent dengue vaccine constructed by recoding contemporary dengue strains to generate safe and immunogenic vaccine components in non-human primates.
Zika live-attenuated vaccine candidate
A codon-deoptimized Zika vaccine candidate demonstrating safety and immunogenicity in non-human primate studies.
Foot-and-mouth disease (FMDV) multivalent vaccine candidate for livestock
Synthetic multivalent live-attenuated vaccine constructs for FMDV designed for livestock, developed in cooperation with agricultural research partners and aimed at scalable cell-culture production.
Services
Collaborative agreements for preclinical and clinical-stage development of vaccine and virotherapeutic candidates, including co-development and licensing discussions.
Partnership arrangements to enable manufacturing scale-up and global distribution of live-attenuated vaccine candidates through external manufacturing and public health partners.
Collaborative agreements for preclinical and clinical-stage development of vaccine and virotherapeutic candidates, including co-development and licensing discussions.
Partnership arrangements to enable manufacturing scale-up and global distribution of live-attenuated vaccine candidates through external manufacturing and public health partners.
Expertise Areas
- Live-attenuated vaccine design
- Genome recoding and synthetic biology
- Oncolytic virotherapeutics
- Computational vaccine design and ML-driven sequence optimization
Key Technologies
- Codon deoptimization / genome recoding
- Codon-pair modification
- AI/ML-assisted sequence design algorithms
- Live-attenuated vaccine platforms